SCHEMBL7882017

SCHEMBL7882017

CN(C(=N)N)C(=O)c1cc2ccc(Oc3cc(CN4CCCC4)ccn3)cc2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.39
RXFP1 Q9HBX9 2/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
SLC6A4 P31645 1/20 0.38
LTA4H P09960 6/20 0.37
BTK Q06187 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
DRD2 P14416 2/20 0.35
DRD3 P35462 2/20 0.35
STAT3 P40763 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
SYK P43405 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7881890 0.87 LOXL2 (0.47) RXFP1KMT2AMEN1
SCHEMBL7880873 0.87 RXFP1 (0.43) FLT3RXFP1KMT2AMEN1BTK
SCHEMBL7881978 0.86 FLT3 (0.40) FLT3RXFP1KMT2AMEN1SLC6A4
SCHEMBL7881140 0.86 RXFP1 (0.45) FLT3RXFP1KMT2AMEN1BTK
SCHEMBL7880055 0.86 CHEK1 (0.34) SLC6A4DRD2DRD3
SCHEMBL7879877 0.86 FLT3 (0.42) FLT3RXFP1KMT2AMEN1BTK
SCHEMBL7884561 0.86 MEN1 (0.44) FLT3RXFP1KMT2AMEN1ROCK2
SCHEMBL7881076 0.85 RXFP1 (0.44) FLT3RXFP1KMT2AMEN1BTK
SCHEMBL7877893 0.84 TLR7 (0.34) FLT3SLC6A4
SCHEMBL7881119 0.84 ROCK2 (0.39) FLT3RXFP1KMT2AMEN1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed